Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH

PloS One
Daniela Carmen OniciuCharles L Bisgaier

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related death. In the United States, NASH affects approximately 2-5% of the population and an additional 10-30% have NAFLD. The number of drugs in development for NASH is growing steadily, along with nonclinical models to support prediction of clinical success. Here we evaluate gemcabene, a first-in-class clinical candidate for dyslipidemia, for its potential utility, based on its combined lipid-lowering and anti-inflammatory efficacy in clinical trials, in a preclinical model of NASH. Gemcabene was evaluated in the STAM™ murine model of NASH. Gemcabene intervention in mice made diabetic with streptozotocin and fed a high fat high-caloric diet was assessed for changes in plasma, and hepatic histological and mRNA markers of lipid metabolism and inflammation. Gemcabene significantly downregulated hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2). These effects are important for the prevention of steatosis, inflammatio...Continue Reading

References

Nov 1, 1993·European Journal of Clinical Investigation·C R SirtoriG Franceschini
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
May 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David E KleinerUNKNOWN Nonalcoholic Steatohepatitis Clinical Research Network
Apr 11, 2008·Clinical Science·Esther M M OoiGerald F Watts
Aug 4, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Koji FujitaAtsushi Nakajima
Mar 12, 2010·PloS One·Susan S BakerLixin Zhu
Apr 30, 2010·The New England Journal of Medicine·Arun J SanyalUNKNOWN NASH CRN
May 14, 2010·Current Opinion in Lipidology·Kevin Jon Williams, Keyang Chen
Nov 5, 2010·Diabetes, Obesity & Metabolism·P Ferré, F Foufelle
May 7, 2011·The Journal of Pathology·Fatima RangwalaAnna Mae Diehl
Jun 29, 2011·Journal of Hepatology·Rohit Kohli, Ariel E Feldstein
Jul 28, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hui-Young LeeGerald I Shulman
Jan 12, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H Carlijne HassingKevin Jon Williams
Feb 12, 2013·Journal of Gastroenterology·Yuki Kawano, David E Cohen
Oct 16, 2013·Nature Reviews. Gastroenterology & Hepatology·Vlad Ratziu
Mar 15, 2014·World Journal of Gastroenterology : WJG·Albert J Czaja
Jun 19, 2014·The New England Journal of Medicine·Anders Berg JørgensenAnne Tybjærg-Hansen
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ekihiro Seki, Robert F Schwabe
Dec 3, 2015·Digestive Diseases and Sciences·Samar H IbrahimGregory J Gores
Aug 23, 2016·Digestive Diseases·Antonia Scherer, Jean-François Dufour
Sep 30, 2016·Journal of Clinical Lipidology·Evan SteinCharles Bisgaier
Nov 4, 2016·Nature Reviews. Gastroenterology & Hepatology·Herbert TilgMichael Roden

❮ Previous
Next ❯

Citations

Feb 1, 2019·Circulation Research·Robert A Hegele, Sotirios Tsimikas
May 8, 2019·European Journal of Preventive Cardiology·Cesare R SirtoriMassimiliano Ruscica
Apr 3, 2020·Expert Opinion on Pharmacotherapy·Yoshio SumidaAtsushi Nakajima
Apr 4, 2020·Postgraduate Medicine·Cezary Wójcik
Jul 21, 2020·American Journal of Physiology. Gastrointestinal and Liver Physiology·Tae Hyo KimLewis Rowland Roberts
Jul 29, 2020·Purinergic Signalling·R Rama SureshKenneth A Jacobson
Jul 28, 2021·Advanced Drug Delivery Reviews·Virender KumarRam I Mahato
Aug 18, 2021·Curēus·Kosisochukwu J Ezeh, Obiora Ezeudemba

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Clinical Trials Mentioned

NCT02548351

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.